HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and ...
Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...
Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies “Arcus stands out as a mid-sized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results